无症状绝经后患者诊断子宫内膜癌是否具有生存优势?以色列妇科肿瘤组研究
以色列妇科肿瘤组回顾性多中心研究比较1607例绝经后子宫内膜癌患者,其中233例无症状、1374例表现为绝经后出血。无症状组与出血组在II-IV期比例、高级别组织学、5年无复发生存、疾病特异性生存和总生存上均无显著差异。结论认为无症状绝经后女性诊断子宫内膜癌不伴更高生存率,对超声诊断子宫内膜息肉或内膜增厚的无症状患者行宫腔镜/刮宫术很少有必要。
要点
- 无症状与出血组II-IV期比例23.5% vs 23.8%(P=.9),高级别组织学41.0% vs 38.4%(P=.12),均无显著差异。
- I期患者中无症状组IA期比例高于出血组(82.1% vs 66.2%,P<.01),辅助术后放疗比例更低(30.5% vs 40.6%,P=.02)。
- 两组5年无复发生存79.1% vs 79.4%(P=.85)、疾病特异性生存83.2% vs 82.2%(P=.57)、总生存79.7% vs 76.8%(P=.37)均无显著差异。
核心结论
- 无症状绝经后女性诊断的子宫内膜癌与更高的生存率无关。
- 对超声诊断子宫内膜息肉或内膜增厚的无症状患者行宫腔镜/刮宫术很少有必要,作者认为可将这些操作保留给超声发现随时间显著改变的患者。
研究设计与样本
- 以色列妇科肿瘤组回顾性多中心研究,纳入1607例绝经后子宫内膜癌患者,其中无症状组233例,绝经后出血组1374例。
- 比较临床、病理和生存指标。
主要发现
- 无症状组与出血组II-IV期比例分别为23.5% vs 23.8%(P=.9),高级别组织学分别为41.0% vs 38.4%(P=.12),均无显著差异。
- I期肿瘤患者中,无症状组IA期比例高于出血组(82.1% vs 66.2%,P<.01),接受辅助术后放疗比例低于出血组(30.5% vs 40.6%,P=.02)。
- 无症状组与出血组5年无复发生存分别为79.1% vs 79.4%(P=.85),疾病特异性生存分别为83.2% vs 82.2%(P=.57),总生存分别为79.7% vs 76.8%(P=.37),均无显著差异。
关键数值与推荐
- 无症状组与出血组II-IV期比例23.5% vs 23.8%(P=.9)。
- 无症状组与出血组高级别组织学比例41.0% vs 38.4%(P=.12)。
- I期患者中无症状组与出血组IA期比例82.1% vs 66.2%(P<.01)。
- I期患者中无症状组与出血组辅助术后放疗比例30.5% vs 40.6%(P=.02)。
- 无症状组与出血组5年无复发生存79.1% vs 79.4%(P=.85),疾病特异性生存83.2% vs 82.2%(P=.57),总生存79.7% vs 76.8%(P=.37)。
临床怎么用
- 作者认为,对超声诊断子宫内膜息肉或内膜增厚的无症状患者行宫腔镜/刮宫术很少有必要。
- 作者认为,将这些操作保留给超声发现随时间显著改变的患者是合理的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Incidental ultrasonographic findings in asymptomatic postmenopausal women, such as thickened endometrium or polyps, often lead to invasive procedures and to the occasional diagnosis of endometrial cancer. Data supporting a survival advantage of endometrial cancer diagnosed prior to the onset of postmenopausal bleeding are lacking. OBJECTIVE: To compare the survival of asymptomatic and bleeding postmenopausal patients diagnosed with endometrial cancer. STUDY DESIGN: This was an Israeli Gynecology Oncology Group retrospective multicenter study of 1607 postmenopausal patients with endometrial cancer: 233 asymptomatic patients and 1374 presenting with postmenopausal bleeding. Clinical, pathological, and survival measures were compared. RESULTS: There was no significant difference between the asymptomatic and the postmenopausal bleeding groups in the proportion of patients in stage II-IV (23.5% vs 23.8%; P = .9) or in high-grade histology (41.0% vs 38.4%; P = .12). Among patients with stage-I tumors, asymptomatic patients had a greater proportion than postmenopausal bleeding patients of stage IA (82.1% vs 66.2%; P < .01) and a smaller proportion received adjuvant postoperative radiotherapy (30.5% vs 40.6%; P = .02). There was no difference between asymptomatic and postmenopausal bleeding patients in the 5-year recurrence-free survival (79.1% vs 79.4%; P = .85), disease-specific survival (83.2% vs 82.2%; P = .57), or overall survival (79.7% vs 76.8%; P = .37). CONCLUSION: Endometrial cancer diagnosed in asymptomatic postmenopausal women is not associated with higher survival rates. Operative hysteroscopy/curettage procedures in asymptomatic patients with ultrasonographically diagnosed endometrial polyps or thick endometrium are rarely indicated. It is reasonable to reserve these procedures for patients whose ultrasonographic findings demonstrate significant change over time.
引用
- Gemer O, Segev Y, Helpman L, et al. Is there a survival advantage in diagnosing endometrial cancer in asymptomatic postmenopausal patients? An Israeli Gynecology Oncology Group study. Am J Obstet Gynecol. 2018. PMID: 29792852. doi:10.1016/j.ajog.2018.05.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。